Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

O Gilan; I Rioja; K Knezevic; MJ Bell; MM Yeung; NR Harker; EYN Lam; C Chung; P Bamborough; M Petretich; M Urh; SJ Atkinson; AK Bassil; EJ Roberts; D Vassiliadis; ML Burr; AGS Preston; C Wellaway; T Werner; JR Gray; AM Michon; T Gobbetti; V Kumar; PE Soden; A Haynes; J Vappiani; DF Tough; S Taylor; SJ Dawson; M Bantscheff; M Lindon; G Drewes; EH Demont; DL Daniels; P Grandi; RK Prinjha; MA Dawson

Journal article

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

O Gilan, I Rioja, K Knezevic, MJ Bell, MM Yeung, NR Harker, EYN Lam, C Chung, P Bamborough, M Petretich, M Urh, SJ Atkinson, AK Bassil, EJ Roberts, D Vassiliadis, ML Burr, AGS Preston, C Wellaway, T Werner, JR Gray Show all

Science | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2020

DOI: 10.1126/science.aaz8455

Abstract

The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions. To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biology and therapy, we developed selective BD1 and BD2 inhibitors. We found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins. BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models, wh..

View full abstract

University of Melbourne Researchers

Enid Lam Author

Dane Vassiliadis Author

Sarah-Jane Dawson Author

Mark Dawson Author

Related Projects (5)

TARGETING THE EPIGENOME FOR THERAPEUTIC GAIN IN CANCER

EVALUATION OF TUMOUR HETEROGENEITY IN THE INITIATION AND MAINTENANCE OF AML AND FOLLOWING RESPONSE TO THERAPY.

CIRCULATING TUMOUR DNA FOR PRECISION MEDICINE

EPIGENETIC THERAPIES AS MOLECULAR PROBES TO INVESTIGATE THE MOLECULAR PATHOGENESIS OF LEUKAEMIA

A major limitation to the success of targeted therapies in cancer is the fact that we have few if any tools to study in detail their mechani..

MOLECULAR PATHOGENESIS OF MIXED LINEAGE LEUKAEMIA

Chromosomal translocations in the MLL gene results in aggressive leukaemias. Several drugs developed to target proteins that interact with t..

Grants

Awarded by Howard Hughes Medical Institute

Funding Acknowledgements

We thank the following funders for fellowship and grant support: a CCV Dunlop fellowship and an HHMI international research scholarship to M.A.D.; a Victoria Cancer Agency fellowship to O.G. and E.Y. N.L.; CRUK to M.L.B.; and a CSL Centenary fellowship to S.J.D. Work from the Dawson laboratory is supported by grant funding from the NHMRC (1106444, 1144649, 1146192), the University of Melbourne, and the Peter MacCallum Foundation.